Chandra D. Lovejoy
Algemeen Adviseur bij ERASCA, INC.
Profiel
Chandra D.
Lovejoy is currently the Chief Regulatory Affairs Officer at Erasca, Inc. Prior to this, Chandra held several positions in the pharmaceutical industry.
From 2007 to 2014, Chandra served as the Vice President of Global Regulatory Affairs at Endocyte, Inc. In 2014, Chandra joined Sierra Oncology, Inc. as the Senior VP of Global Regulatory Affairs & Head of Quality, a position held until 2017.
From 2017 to 2021, Chandra worked as the Vice President of Regulatory Affairs at G1 Therapeutics, Inc. Chandra's earlier experience includes a managerial role in Regulatory Affairs at Genentech, Inc. from 2005 to 2007.
Chandra completed a graduate degree at San Diego State University and an undergraduate degree at the University of San Francisco.
Actieve functies van Chandra D. Lovejoy
| Bedrijven | Functie | Begin |
|---|---|---|
| ERASCA, INC. | Algemeen Adviseur | - |
Eerdere bekende functies van Chandra D. Lovejoy
| Bedrijven | Functie | Einde |
|---|---|---|
| G1 THERAPEUTICS, INC. | Algemeen Adviseur | 01-04-2021 |
| SIERRA ONCOLOGY, INC. | Algemeen Adviseur | 01-01-2017 |
| ENDOCYTE, INC. | Algemeen Adviseur | 01-01-2014 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Algemeen Adviseur | 01-11-2007 |
Opleiding van Chandra D. Lovejoy
| University of San Francisco | Undergraduate Degree |
| San Diego State University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| G1 THERAPEUTICS, INC. | Health Technology |
| ERASCA, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |